Navigation Links
Elliott 'Extremely Dissatisfied' With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
Date:9/6/2007

Major Shareholder Will NOT Vote for Merger; Says 'Shareholders Have Already

Spoken' by Rejecting Tender Offer at $5.60 per Share

NEW YORK, Sept. 6 /PRNewswire-FirstCall/ -- Elliott Associates, L.P. (together with funds under common management), a major shareholder of Bioenvision (Nasdaq: BIVN), today said the following letter has been sent to the Board of Directors:

September 5, 2007

The Board of Directors

Bioenvision, Inc.

345 Park Avenue, 41st Floor

New York, NY 10154

Dear Members of the Board of Directors:

I write to you on behalf of Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott" or "we"), which collectively own approximately 6.7% of the common stock of Bioenvision, Inc. (the "Company" or "Bioenvision"). Elliott is extremely dissatisfied with the proposed Genzyme transaction, in which Bioenvision shareholders are to receive $5.60 per Company share (the "Genzyme Transaction"), because we strongly believe this transaction significantly undervalues Bioenvision. We believe this outcome was the result of a hurried and flawed sale process, apparent conflicts-of- interest on the part of the Board, and a miscalculation by the Company that shareholders would prefer a sale at any price rather than to wait for the significant value to which we are entitled.

Elliott will NOT vote for the Genzyme Transaction. It is clear to us that other stockholders share our view as Genzyme's tender offer attracted virtually no support apart from that of the shareholders who orchestrated the transaction. While we agree that a sale of Bioenvision may ultimately be the best course of action, it is our firm view that remaining a stand-alone entity is far preferable to the currently proposed $5.60 per share offer.

We feel compelled to point out to the Board some of the serious issues that other shareholders, equity research analysts and informed parties have raised regarding: i) the faulty process undertaken in selling the Company; ii) the outrageously low valuation at which Genzyme is attempting to appropriate Bioenvision; and iii) the lack of support for Genzyme's offer by the owners of the Company.

Flawed Sale Process

We believe the process undertaken by the Board in the sale of Bioenvision fell short of your fiduciary obligation to maximize shareholder value. Given the facts that Bioenvision had received a (dilutive) infusion of capital less than two months prior to agreeing to sell the Company and that directors associated with Perseus-Soros, the Company's largest shareholder and an eager seller of stock, were intimately involved in the sale process, we would have assumed that the sale process would have reflected a vastly higher duty of care. The recent capital raise provided the Company with liquidity and the Board involvement of a large, motivated seller of stock provided the Board with even greater reason, beyond its fiduciary obligations, to conduct a robust process to negate even the slightest appearance of a conflict-of- interest.

In our opinion, it would not be an exaggeration to state that this sale process had a greater resemblance to a "fire sale" than an auction. With substantial cash in the bank, a growing revenue stream, a currently approved and highly promising product, and positive catalysts around the corner, the (unconflicted) Board members had absolutely no need to rush to sell the Company, let alone to hurriedly accept such an inadequate offer.

Vastly Inadequate Valuation

Some of the facts that we have considered, and that the Board should have contemplated, in evaluating the $345 million, or $5.60 per share, proposal are as follows:

i) In a September 2006 corporate investor presentation, Bioenvision

presented a slide entitled, "Evoltra - Global Blockbuster Potential"

(Evoltra is the brand name for clofarabine) showing an estimated total

market potential for clofarabine of $1.3 billion, excluding the

potential to treat solid tumors and autoimmune diseases.

ii) Genzyme's view of clofarabine, as discussed on the May 29, 2007

conference call with investors, is that it will reach $600 million of

revenue. Note that this view selectively incorporates only the

pediatric ALL, adult AML and MDS indications and was supplied by the

acquirer who just announced a very favorable purchase price for this

revenue stream.

iii) The lion's share of equity research price targets were far higher

than the $5.60 per share Genzyme offer price. UBS, the bank providing

the "fairness opinion" to the Board, had a $13 price target (132%

higher than the Genzyme Transaction). AG Edwards had a $9 price target

(61% higher than the Genzyme Transaction). Rodman and Renshaw had a

$12 price target (114% higher than the Genzyme Transaction). CIBC had

an $8 price target (43% higher than the Genzyme Transaction).

Oppenheimer had an $11 price target (96% higher than the Genzyme

Transaction). In fact, of all the coverage on the Street, we could

only find one price target below the $5.60 per share offered by Genzyme

(Fortis Bank).

Furthermore, in evaluating clofarabine, Elliott retained expert life science consultants to complete their own, independent projections. Our consultants conceded that while the current application to the EMEA would likely require additional data (which has now been affirmed), they found clofarabine to be a novel compound with "several potential advantages" over current treatment options. Most importantly, they conservatively estimated that in only two indications (pediatric ALL and elderly AML), clofarabine's market potential is in excess of $420 million (this compares to Bioenvision's estimate for these two markets of $600 million) and that additional indications would yield additional revenue opportunities. The Board could have commissioned these independent projections just as easily as Elliott.

Given these facts, exacerbated by the complete lack of a need to sell the Company, we are simply astonished by the valuation agreed to by the Board.

And we aren't alone. The Board can read the published equity research reports commenting on the valuation but, most importantly, by refusing to tender their shares, shareholders have already spoken.

Lack of Support for the Current Offer

If shareholders were interested in receiving $5.60 per share, they would have tendered back in June. The fact that nearly no one - apart from insiders - did so should have sent a very clear message - $5.60 per share is insufficient consideration.

Looking over your concentrated shareholder base, it seems that Elliott is in the company of a number of well-informed and independent investors who have reached the same conclusion. As such, we see no reason whatsoever why the outcome will be any different in the upcoming shareholder vote. Given the price that shares have recently been trading, anyone desirous of receiving $5.60 has likely sold their shares in the market. Investors with greater return expectations will likely continue to hold the stock and vote against the Genzyme Transaction.

Certainly, we are among those with far greater return expectations.

To be clear, we are not opposed to the concept of a sale of the Company and, in fact, believe that Bioenvision is a strong complement to Genzyme. Our issue isn't the decision to sell; it is the price at which the Board proposes to give away the Company. At a fair valuation, the Board would receive our support.

We remain confident in Bioenvision's prospects and available to discuss our thoughts on the situation with the Board.

Sincerely,

sig/

Jesse A. Cohn

Senior Technology Analyst

About Elliott Associates, L.P.

Elliott Associates, L.P. and its sister fund, Elliott International, L.P. have more than $8 billion of capital under management as of July 1, 2007. Founded in 1977, Elliott Associates is one of the oldest hedge funds under continuous management. The Elliott funds' investors include large institutions, high-net-worth individuals and families, and employees of the firm.

(i) Bioenvision's share of this revenue, approximately 50%, is a multiple

of the $345 million purchase price in the Genzyme Transaction, which

ignores the fact that biotech companies typically trade at high

multiples of future revenue. Additionally, the $1.3 billion revenue

figure doesn't incorporate all indications.

(ii) Even assuming this severely discounted and incomplete revenue

estimate, the $345 million valuation is inadequate.


'/>"/>
SOURCE Elliott Associates, L.P.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Binge eating extremely common in restaurants
3. Drugs Delivery Revolutionized by Extremely Stable Glass
4. Risk of Heart Attack, Death High Among Extremely Anxious Patients
5. Reminiscing Into The Past Makes You Dissatisfied With The Present
6. Americans Dissatisfied with their Health Care
7. Dissatisfied Marriage Have a Bad Effect on the Health of Older Adults
8. Patients Dissatisfied Following Closed Reduction Of Nasal Fractures
9. Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients
10. Jade Goody Believes Miscarriage was Gods Punishment for Wrong Deeds
11. Luciano Pavarotti Believes He is nearing His End
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today reported its fourth quarter and full year ... vivo therapeutic genome editing," said Edward Lanphier, ... finger nuclease (ZFN) technology leads the therapeutic genome ... competencies necessary to move our ground-breaking genome editing ...
Breaking Medicine Technology: